Guardant Health (GH): Revenue +44%, Shield Volume 4x — Why We Still Say AVOID at $162

Guardant Health, Inc. (GH) Q2 2026 — Q2 2026 = the three months ended 30 June 2026, reported after the close on 30 July. Revenue $334.98M vs $232.09M (+44.3%) vs ~$314M consensus; non-GAAP loss $0.42/sh vs ~$0.75 expected. Shield revenue $52.9M on ~66,000 tests from $14.8M and ~16,000. FY26 guidance RAISED to $1.34-1.36B. Stock +6.3% to $161.99. Guardant Health grew revenue 44%, quadrupled Shield screening volume and raised every line of guidance — and the stock has already tripled. Our model says AVOID. THE CALL: AVOID (3/5, EXCEPTIONAL COMPANY, IMPOSSIBLE PRICE) — base-case value ~$100.0 vs ~$161.99 today. KEY METRICS: - Revenue $334.98M vs $232.09M (+44.3%), above the ~$314M consensus. Oncology $219.1M (+38%) on ~104,000 tests (+63%); Biopharma & Data $60.9M (+9%); Screening $52.9M vs $14.8M (+257%) on ~66,000 Shield tests vs ~16,000 - THE EPS TRAP: GAAP loss was $0.90/sh (vs $0.80 LY), but the figure analysts modelled is the NON-GAAP loss of $0.42 vs about $0.75 expected — a clear beat. The gap is $62.4M of stock comp. Feeds flashing a 'miss' compare a GAAP actual to a non-GAAP estimate - COST OF THE GROWTH: opex of $348.1M EXCEEDED the $335.0M of revenue. S&M $190.0M (+58.8%, 57% of revenue) grew far faster than the top line; R&D $96.5M; G&A $61.7M. Operating loss $129.1M, net loss $120.1M, adj. EBITDA -$55.9M, FCF -$69.5M. Gross margin 65% GAAP / 67% non-GAAP - GUIDANCE RAISED ON EVERY LINE: FY26 revenue $1.34-1.36B (+36-38%) from $1.30-1.32B. Shield volume 270-285k tests from 230-245k; screening revenue $218-230M from $186-198M; oncology volume ~+50% from ~35%. FCF burn $195-205M (raised) vs $233M in 2025 - THE CATCH NOBODY FLAGGED: 1H26 free-cash burn was $140.7M, so the FY guide leaves only $54-64M for the ENTIRE second half — quarterly burn must fall from ~$70M to ~$30M immediately, while management says lab capacity investment is ACCELERATING - BALANCE SHEET: $1.053B cash plus $114.3M restricted = $1.17B, roughly six years of runway — no financing cliff. Against $1.503B of convertible notes = ~$335M net debt. Liabilities $2.14B exceed assets $1.91B: stockholders' DEFICIT $222.9M, accumulated deficit $3.23B - WHAT RE-RATED IT: Shield added to American Cancer Society colorectal screening guidelines; UnitedHealth the first major commercial payer (from 1 Aug 2026); FDA approval of Guardant360 Liquid CDx and of a lower-COGS Shield workflow. The stock is up ~295% in twelve months - OUR VALUATION (no owner-earnings DCF — GH burns cash): opex must fall from 81% of revenue to under ~68%; operating break-even FY2028, FCF-positive FY2029. Three-scenario DCF on ~145M diluted shares: bear $38 / base $85 / bull $160 at 10%; weighted $92. We publish ~$100 vs $161.99 = -38% - REVERSE DCF: at $161.99 the enterprise value is $22.0B — 16x FY26E revenue, 12.9x FY27E. At a 10% discount and 3.5% terminal growth that price demands $1.43B of free cash flow STARTING NOW, against -$0.20B today; our base case doesn't reach it until 2035 - STREET: Buy (29 buy / 0 hold / 1 sell, 30 analysts), average target $178.73, range $120-$210 = about +10%. Stifel raised to $180 from $130 post-print; Bernstein $200 and BTIG $190 on the UnitedHealth news. We DIFFER on the rating and are far more CAUTIOUS on the number What to watch: Bullish: Q3 free cash burn better than -$35M validates the guide and pulls our profitability path forward a year. Bearish: Shield revenue/test below ~$800, or any trim to the 270-285k volume guide. We'd start buying near $95. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.